2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4566 GLP-1 receptor agonists are associated with lower mortality and infection without increased skeletal-related events in multiple myeloma with type 2 diabetes

Anas Odeh, MD, Anwar Zahran, MD2, Hamed Daw, MD, DO3, Shahzad Raza, MD4, Ameed Bawwab, MD5, Lana Khatib6, Abdo Haddad, MD7
1 Cleveland Clinic, Cleveland, Ohio, United States
2 An Najah National University, Nablus, Palestine
3 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
4 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

Background: Patients with multiple myeloma (MM) frequently have type 2 diabetes mellitus (T2DM) and are vulnerable to treatment-related renal, infectious, and skeletal complications. GLP-1 receptor agonists (GLP-1RAs) have established cardiometabolic and kidney benefits, but concerns persist regarding bone quality and weight loss in a skeletally vulnerable population, and their impact during active MM therapy is unknown. We compared skeletal-related events (SREs), renal outcomes, infection, and mortality in GLP-1RA users versus an active comparator receiving dipeptidyl peptidase-4 inhibitors (DPP-4i), matched for glycemic indication but lacking cardiorenal effect.

Methods: Retrospective cohort study using the TriNetX Global Collaborative Network (181 healthcare organizations). Adults with T2DM (ICD-10 E11) and MM (C90.0) between January 2010 and July 2023 who initiated a GLP-1RA (n=533) or DPP-4i (n=1,152) within 5 years of the T2DM/MM index, with MM-directed therapy (proteasome inhibitors, immunomodulators, anti-CD38 antibodies, bispecifics/CAR-T, alkylators) given 6 months before to 3 months after incretin initiation; patients exposed to the alternate antihyperglycemic class were excluded. Propensity score matching incorporated demographics, renal and skeletal comorbidities, stem-cell transplantation, MM-directed and bone-modifying therapies, other glucose-lowering drugs, corticosteroids, and laboratory measures (albumin, hemoglobin, creatinine, eGFR, beta-2-microglobulin, HbA1c, BMI), yielding 413 per cohort. The primary outcome was an SRE composite of pathologic fracture, cord compression, vertebral augmentation, radiotherapy, or hypercalcemia. Secondary outcomes were acute kidney injury (AKI), chronic kidney disease (CKD), dialysis, infection (pneumonia/influenza or sepsis), and all-cause mortality, assessed at 1, 2, and 3 years. Patients with the respective outcome before follow-up were excluded from that analysis. Kaplan-Meier hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated.

Results: Before matching, GLP-1RA users were younger (64.5 vs 69.3 years), heavier (BMI 34.3 vs 29.4 kg/m2), and less likely to have CKD (27.6% vs 37.6%); matching eliminated these differences (age 65.8 vs 65.5; BMI 33.2 vs 32.0; CKD 27.6% vs 29.3%), with standardized differences <0.1 for nearly all covariates. Matched cohorts were 61% male, with 27% prior transplant, 40% lenalidomide, and 70% corticosteroid exposure. SRE risk was similar at 1 year (7.7% vs 8.7%; HR 0.87, 95% CI 0.50-1.52), 2 years (11.4% vs 12.2%; HR 0.92, 0.58-1.45), and 3 years (16.1% vs 14.4%; HR 1.10, 0.73-1.65). In contrast, all-cause mortality was consistently lower with GLP-1RA at 1 year (6.6% vs 12.4%; HR 0.52, 0.32-0.83), 2 years (12.9% vs 24.1%; HR 0.50, 0.36-0.70), and 3 years (17.8% vs 29.6%; HR 0.55, 0.41-0.74; all log-rank P<0.01), with 3-year survival of 80.5% vs 67.8%. Infection risk was lower at 2 years (23.2% vs 34.3%; HR 0.63, 0.46-0.87) and 3 years (29.8% vs 39.0%; HR 0.71, 0.53-0.94), with a consistent 1-year trend (17.5% vs 22.7%). AKI was lower at 2 years (17.0% vs 24.5%; HR 0.66, 0.45-0.96) and directionally lower at 3 years (21.4% vs 28.2%; HR 0.72, 0.51-1.01). CKD (3-year 21.7% vs 24.6%; HR 0.82, 0.58-1.18), dialysis (3.8% vs 5.3%; HR 0.67, 0.34-1.30), and hypercalcemia (6.5% vs 8.8%; HR 0.70, 0.41-1.19) were numerically lower without reaching significance; pathologic fracture and radiotherapy did not differ.

Conclusions: In propensity-matched patients with T2DM receiving active MM therapy, GLP-1RA exposure was associated with approximately 45-50% lower mortality across three years, together with lower infection and AKI risk, and without any excess of skeletal-related events, fractures, hypercalcemia, or palliative radiotherapy. The dissociation between a strong survival, infection, and renal signal and neutral skeletal outcomes argues against a bone-mediated effect and favors systemic mechanisms: attenuated inflammation, preserved renal and metabolic reserve, and better tolerance of MM-directed therapy. Its magnitude, stability across horizons, and emergence within the first year suggest an early, durable benefit. These data provide the first outcome evidence for GLP-1RAs during active myeloma therapy and support prospective evaluation in this population. Findings are hypothesis-generating and subject to residual confounding inherent to retrospective analysis.

Anas Odeh, MD: No relevant conflicts of interest to declare.